FDA Allows Orphan Drug Status for Low-Dose Naltrexone to Treat CRPS to Soin Therapeutics
Soin Therapeutics, a pharmaceutical company, based in Dayton, OH, was granted orphan drug status from the FDA for low dose naltrexone (LDN) to treat complex regional pain syndrome (CRPS). Soin Therapeutics is currently developing its unique formulation of low-dose naltrexone. The formulation works on